Literature DB >> 8126705

Modulation of the kynurenine pathway in search for new neuroprotective agents. Synthesis and preliminary evaluation of (m-nitrobenzoyl)alanine, a potent inhibitor of kynurenine-3-hydroxylase.

R Pellicciari1, B Natalini, G Costantino, M R Mahmoud, L Mattoli, B M Sadeghpour, F Moroni, A Chiarugi, R Carpenedo.   

Abstract

The synthesis of (o-nitrobenzoyl)-, (m-nitrobenzoyl)-, and (p-nitrobenzoyl)alanine (o-, m-, and p-NBA), three new kynurenine analogues, and their evaluation as inhibitors of kynureninase and kynurenine-3-hydroxylase are reported. The most potent of these compounds, m-NBA, has an IC50 of 0.9 +/- 0.1 microM as an inhibitor of kynurenine-3-hydroxylase and of 100 +/- 12 microM as an inhibitor of kynureninase. When administered to rats, m-NBA significantly increases the concentration of kynurenine and kynurenic acid in the brain as well as in blood and in the liver. m-NBA has also been shown to increase the concentration of kynurenic acid in hippocampal extracellular fluid. This increase is associated with sedative and anticonvulsant activities, thus confirming the possibility of antagonizing L-glutamate-mediated effects by modulating the kynurenine pathway of L-tryptophan metabolism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8126705     DOI: 10.1021/jm00031a015

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  21 in total

Review 1.  Is there a role for immune-to-brain communication in schizophrenia?

Authors:  Golam M Khandaker; Robert Dantzer
Journal:  Psychopharmacology (Berl)       Date:  2015-06-04       Impact factor: 4.530

2.  Modulation of the function of presynaptic alpha7 and non-alpha7 nicotinic receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in mouse brain.

Authors:  M Grilli; L Raiteri; L Patti; M Parodi; F Robino; M Raiteri; M Marchi
Journal:  Br J Pharmacol       Date:  2006-10-03       Impact factor: 8.739

3.  Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?

Authors:  H-Q Wu; A Rassoulpour; R Schwarcz
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

Review 4.  Kynurenines in the CNS: recent advances and new questions.

Authors:  László Vécsei; Levente Szalárdy; Ferenc Fülöp; József Toldi
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

5.  The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

Authors:  C Hilmas; E F Pereira; M Alkondon; A Rassoulpour; R Schwarcz; E X Albuquerque
Journal:  J Neurosci       Date:  2001-10-01       Impact factor: 6.167

6.  Kynurenine pathway metabolites in humans: disease and healthy States.

Authors:  Yiquan Chen; Gilles J Guillemin
Journal:  Int J Tryptophan Res       Date:  2009-01-08

7.  Role of kynurenines in the neurotoxic actions of kainic acid.

Authors:  W M Behan; T W Stone
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

Review 8.  Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.

Authors:  Robert Schwarcz; Paolo Guidetti; Korrapati V Sathyasaikumar; Paul J Muchowski
Journal:  Prog Neurobiol       Date:  2009-04-24       Impact factor: 11.685

9.  The Janus-face kynurenic acid.

Authors:  Eva Rózsa; Hermina Robotka; László Vécsei; József Toldi
Journal:  J Neural Transm (Vienna)       Date:  2008-04-30       Impact factor: 3.575

10.  Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice.

Authors:  Ping Yu; Nicholas A Di Prospero; Michael T Sapko; Tao Cai; Amy Chen; Miguel Melendez-Ferro; Fu Du; William O Whetsell; Paolo Guidetti; Robert Schwarcz; Danilo A Tagle
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.